Company Profile

Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
LHA Investor Relations
Yvonne Briggs
T: 310-691-7100
ybriggs@lhai.com

Company Contact
Anebulo Pharmaceuticals, Inc.
1415 Ranch Road 620 South
Austin, TX 78734
T: 512-598-0931
ir@anebulo.com